News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th
Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater
The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28
Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St
Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.
Medical-device maker Boston Scientific said that it is unlikely to meet its sales growth and earnings expectations for the year, citing a major cyberattack disclosed last month that left it unable to fill orders.
On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
Boston Scientific said Tuesday a cybersecurity incident is likely to have a material impact on its third-quarter and full-year results.
MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.
Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Sept 8 () - Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 results. The medical device maker is unlikely to meet its previously issued third-quarter and full-year sales and adjusted profit forecast, it said in a regulatory filing.
Boston was hit by a cyberattack on 25 August that caused widespread disruption to its global operations.
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
The company is working through a backlog after the cyberattack hampered manufacturing, order processing and shipping.
In recent weeks, Boston Scientific has faced multiple voluntary global recalls of its Suture Cinch endoscopic devices and ENROUTE Transcarotid Neuroprotection systems, alongside a cybersecurity incident that disrupted operations and led to reduced full‑year 2026 sales and earnings guidance. These simultaneous product quality issues, operational disruptions, and softer demand for key franchises raise fresh questions about the resilience of Boston Scientific’s previously growth-focused...
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Boston Scientific (BSX) is back in focus after a series of voluntary global recalls affecting its ENROUTE Transcarotid Neuroprotection Systems and OverStitch Suture Cinch devices, along with a separate cybersecurity incident that has disrupted operations and lowered 2026 guidance. Against this backdrop of recalls and a cybersecurity disruption, Boston Scientific’s recent share price performance has weakened. The stock is at US$48.37 with a year-to-date share price decline of 48.93%, alongside...
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.